Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$70.10 USD

70.10
1,222,449

-0.19 (-0.27%)

Updated Oct 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?

Celldex Therapeutics, Inc. (CLDX) is expected to report fourth-quarter 2016 results on Mar 4 after market close.

    Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?

    Aerie Pharmaceuticals, Inc. (AERI) is expected to report fourth-quarter 2016 results on Mar 7.

      Arpita Dutt headshot

      Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals

      Key updates this week include earnings results from companies like BioMarin and positive data on Kite's (KITE) lead pipeline candidate.

        BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat

        BioMarin Pharmaceutical Inc. (BMRN) reported a loss of 37 cents per share in the fourth quarter of 2016.

          Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More

          The fourth-quarter earnings season is drawing to a close with results from 411 S&P 500 members or 82.2% of the index's total membership already out, as of Feb 22, 2017.

            Arpita Dutt headshot

            Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising

            While Alexion (ALXN) reported a mixed quarter, Celgene provided promising data on a pipeline candidate.

              BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?

              We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports fourth-quarter and full-year 2016 results on Feb 23

                Can Wright Medical (WMGI) Surprise Investors in Q4 Earnings?

                Wright Medical Group N.V. (WMGI) is scheduled to release fourth-quarter 2016 results on Feb 21.

                  LabCorp (LH) Q4 Earnings: What's in the Cards for the Stock?

                  Laboratory Corp. of America Holdings (LH), or LabCorp, is expected to report fourth-quarter 2016 results before the market opens on Feb 16.

                    What's in Store for ImmunoGen (IMGN) this Earnings Season?

                    ImmunoGen, Inc. (IMGN) is scheduled to report results for the three months ended Dec 31, 2016 on Feb 17, before the opening bell. Overall, the company has posted an average negative surprise of 19.34%.

                      Will Zoetis (ZTS) Disappoint Estimates This Earnings Season?

                      Zoetis Inc. (ZTS) is scheduled to report fourth-quarter and full year 2016 results on Feb 16 before the market opens.

                        Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?

                        Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report fourth-quarter and full-year 2016 results on Feb 16.

                          Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?

                          Perrigo Company plc (PRGO) is expected to report fourth-quarter 2016 results this month. Perrigo has a mixed track record as the company beat expectations in two of the last four quarters and missed the same in the other two.

                            Teva (TEVA) Q4 Earnings: What's in Store for the Stock?

                            Teva Pharmaceutical Industries Ltd. (TEVA) will be reporting fourth-quarter 2016 and full-year earnings on Feb 13, before the market opens.

                              Swarup Gupta headshot

                              5 Great Biotech Stocks to Buy Now

                              Biotechs have stabilized and still offer the potential to deliver substantial returns.

                                BioMarin's Hemophilia Candidate Included in PRIME Initiative

                                BioMarin Pharmaceutical Inc. (BMRN) announced that BMN 270, being evaluated for the treatment for severe hemophilia A, has been granted access to Priority Medicines (PRIME), a regulatory initiative by the European Medicines Agency (EMA).

                                  Is BioMarin (BMRN) Well Poised for Growth in 2017?

                                  We issued an updated research report on BioMarin Pharmaceutical Inc. (BMRN) on Jan 25.

                                    The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen

                                    The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen

                                      Arpita Dutt headshot

                                      3 Overlooked Drug Stocks to Watch Out for in 2017

                                      As we start the New Year, here is a look at 3 drug stocks that have not been in the news much but have been witnessing upward estimate revisions and sport a strong Zacks Rank.

                                        BioMarin (BMRN) Raised to Buy: Should You Add the Stock?

                                        The Zacks Investment Research upgraded BioMarin (BMRN) to a Zacks #2 Rank (Buy).

                                          Indradip Ghosh headshot

                                          New Strong Buy Stocks for October 24th

                                          Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

                                            Tirthankar Chakraborty headshot

                                            New Strong Buy Stocks for October 17th

                                            Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

                                              Tirthankar Chakraborty headshot

                                              New Strong Buy Stocks for October 6th

                                              Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

                                                5 Biotech Stocks to Bet on This Earnings Season

                                                The happening biotech sector should be a good bet for investors.